Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

Chloe Orkin, Christine Katlama, Pierre‐Marie Girard et al.|The Lancet HIV|2023

Cited by 31